Andrew Hopkins, Exscientia CEO

October 1, 2021 07:15 AM EDTUpdated 10:45 AM

The cash won't stop for Exscientia as it makes a $300M+ Nasdaq debut

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Omada Health is going public on Friday at a $1.1B valuation

GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs

Otsuka spells out Phase 3 win in rare kidney disease, Vera’s stock takes a hit

Biopharma leaders carving a path for the industry’s LGBTQ+ community

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...